Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03512275 · ClinicalTrials.gov registry record · Phase 2
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT03512275 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 42 participants.
The verdict
NCT03512275, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
Interventions
- DRUG Bermekimab Monoclonal Antibody 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-06-20 |
| Est. Completion | 2019-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03512275
The ClinicalTrials.gov registry entry for NCT03512275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bermekimab Monoclonal Antibody 400 mg is the first listed.
NCT03512275 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03512275 about?
NCT03512275 is a clinical study titled "A Study of Bermekimab in Patients With Hidradenitis Suppurativa". Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
What is the current status of trial NCT03512275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2018-06-20. Estimated completion is 2019-01-14.
What interventions are being tested in trial NCT03512275?
The interventions under investigation include: Bermekimab Monoclonal Antibody 400 mg (DRUG).
Who is sponsoring clinical trial NCT03512275?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.